Author: Sagimet Biosciences Inc.

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

February 11, 2026
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

February 2, 2026

1 2

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences